Yang HY, Xia YQ, Hou YJ, Xue P, Zhu SJ, Lu DR. Chemotherapy combined with bevacizumab for small cell lung cancer with brain metastases: A case report. World J Clin Cases 2024; 12(2): 405-411 [PMID: 38313643 DOI: 10.12998/wjcc.v12.i2.405]
Corresponding Author of This Article
Dian-Rong Lu, Doctor, PhD, Chief Physician, Professor, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, No. 6 Huajiadi Street, Chaoyang District, Beijing 100102, China. ludianrong@aliyun.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Hong-Yu Yang, Yu-Jia Hou, Peng Xue, Shi-Jie Zhu, Dian-Rong Lu, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China
Hong-Yu Yang, Department of Oncology, Tianjin University of Chinese Medicine, Tianjin 300000, China
Yu-Qing Xia, Department of Electrothermal Acupuncture, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China
Yu-Qing Xia, Department of Acupuncture and Moxibustion, Sihui Hospital of Traditional Chinese Medicine, Beijing 100102, China
Author contributions: Yang HY drafted the manuscript; Xia YQ and Hou YJ reviewed the literature and participated in drafting the manuscript; Xue P and Zhu SJ and Lu DR revised the manuscript for important intellectual content; All authors have approved the final manuscript.
Supported byYu-Qing Xia Famous Old Chinese Medicine Heritage Workshop of “3+3” Project of Traditional Chinese Medicine Heritage in Beijing, Jing Zhong Yi Ke Zi (2021), No. 73; National Natural Science Foundation of China, No. 81973640; Nursery Program of Wangjing Hospital, Chinese Academy of Traditional Chinese Medicine, No. WJYY-YJKT-2022-05; China Academy of Traditional Chinese Medicine Wangjing Hospital High-Level Chinese Medicine Hospital Construction Project Chinese Medicine Clinical Evidence-Based Research: The Evidence-Based Research of Electrothermal Acupuncture for Relieving Cancer-Related Fatigue in Patients With Malignant Tumor, No. WYYY-XZKT-2023-20.
Informed consent statement: The patient signed an informed consent form before receiving treatment and agreed to publish the case.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read CARE Checklist (2016), and the manuscript was prepared and revised according to CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dian-Rong Lu, Doctor, PhD, Chief Physician, Professor, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, No. 6 Huajiadi Street, Chaoyang District, Beijing 100102, China. ludianrong@aliyun.com
Received: September 29, 2023 Peer-review started: September 29, 2023 First decision: December 18, 2023 Revised: December 18, 2023 Accepted: December 26, 2023 Article in press: December 26, 2023 Published online: January 16, 2024 Processing time: 91 Days and 1.6 Hours
Core Tip
Core Tip: Small cell lung cancer (SCLC) accounts for approximately 13%-15% of all lung cancer patients. A five-year survival rate of less than 7 percent makes it one of the deadliest cancers. Compared to Non-Small Cell Lung Carcinoma, SCLC has a faster doubling time in the early stages and is more likely to spread widely. Therefore, 60%-70% of SCLC is diagnosed as extensive stage at initial diagnosis. SCLC cells also show a high tendency of metastasis to the central nervous system, and 10% of patients have brain metastasis at the first visit. Here, we report a patient with extensive stage-small cell lung cancer (ES-SCLC) and brain metastases who received four lines of treatment. We used bevacizumab in combination with irinotecan as a post-fourth-line therapy in an elderly man and achieved a significant partial response.
